Literature DB >> 7791107

Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.

E A Walker1, G Zernig, J H Woods.   

Abstract

The apparent in vivo dissociation constant (KA) and relative efficacy values for alfentanil, etonitazene, morphine, and nalbuphine were determined by comparing the effects of these agonists in the presence of buprenorphine with the effects of these agonists alone in the rhesus monkey tail-withdrawal procedure. Initial time course studies of buprenorphine alone indicated that 3.2 and 10 mg/kg produced increases in tail-withdrawal latencies when studied with 48 degrees C water for 48 hr. No increases in tail-withdrawal latency were found with either dose studied with 55 degrees C water. Buprenorphine produced dose-dependent shifts to the right for the antinociceptive effects of alfentanil, etonitazene, morphine and nalbuphine 72 hr after administration and decreased the maximal effects of morphine in 48 degrees C water and those of alfentanil and etonitazene in 55 degrees C water. Buprenorphine administration decreased the receptors available for agonist interaction to approximately 2%. The average apparent in vivo dissociation constant (KA) values for alfentanil, etonitazene, morphine and nalbuphine were 3.3, 0.073, 60 and 31 mg/kg, respectively. High efficacy estimates were determined for alfentanil (149-203) and etonitazene (174-203), whereas lower efficacy estimates were determined for nalbuphine (57) and morphine (17). The apparent in vivo dissociation constant of a pseudoirreversible antagonist (KB) value for buprenorphine averaged 0.15 mg/kg across agonists, temperatures and buprenorphine doses. These data extend and emphasize the significance of in vivo estimates of affinity and relative efficacy for drug classification.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791107

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta).

Authors:  Alexis L Mackiewicz; Gregory W Salyards; Heather K Knych; Ashley E Hill; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-06-21       Impact factor: 1.232

2.  A role for the mu opioid receptor in the antidepressant effects of buprenorphine.

Authors:  Shivon A Robinson; Rebecca L Erickson; Caroline A Browne; Irwin Lucki
Journal:  Behav Brain Res       Date:  2016-11-03       Impact factor: 3.332

3.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

4.  Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.

Authors:  Sandra D Comer; Maria A Sullivan; Ellen A Walker
Journal:  J Pharmacol Exp Ther       Date:  2005-09-06       Impact factor: 4.030

5.  Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Authors:  Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2018-11-21       Impact factor: 4.030

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception.

Authors:  Phillip A Saccone; Angela M Lindsey; Robert A Koeppe; Kathy A Zelenock; Xia Shao; Phillip Sherman; Carole A Quesada; James H Woods; Peter J H Scott
Journal:  J Pharmacol Exp Ther       Date:  2016-09-13       Impact factor: 4.030

8.  Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Authors:  Carol A Paronis; Spyros P Nikas; Vidyanand G Shukla; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

9.  Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Authors:  Colette M Cremeans; Erin Gruley; Donald J Kyle; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

10.  Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in rats.

Authors:  Ahmad A Altarifi; Laurence L Miller; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2012-10       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.